Century Therapeutics (IPSC) Enterprise Value (2022 - 2025)
Historic Enterprise Value for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$204.2 million.
- Century Therapeutics' Enterprise Value rose 4704.41% to -$204.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$204.2 million, marking a year-over-year increase of 4704.41%. This contributed to the annual value of -$343.4 million for FY2024, which is 1014.77% up from last year.
- Per Century Therapeutics' latest filing, its Enterprise Value stood at -$204.2 million for Q3 2025, which was up 4704.41% from -$251.2 million recorded in Q2 2025.
- Century Therapeutics' 5-year Enterprise Value high stood at -$156.4 million for Q2 2023, and its period low was -$415.3 million during Q2 2024.
- For the 4-year period, Century Therapeutics' Enterprise Value averaged around -$297.1 million, with its median value being -$315.5 million (2022).
- Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 5870.79% in 2023, then crashed by 16554.15% in 2024.
- Quarter analysis of 4 years shows Century Therapeutics' Enterprise Value stood at -$315.5 million in 2022, then dropped by 21.14% to -$382.2 million in 2023, then rose by 10.15% to -$343.4 million in 2024, then soared by 40.54% to -$204.2 million in 2025.
- Its Enterprise Value stands at -$204.2 million for Q3 2025, versus -$251.2 million for Q2 2025 and -$293.4 million for Q1 2025.